CD274 and non-small cell lung carcinoma: In the KEYNOTE 010 study, pembrolizumab continued to provide greater long-term benefit than docetaxel in patients with previously treated advanced NSCLC, with both PD-L1 TPS ≥ 50% and ≥1%.